IP Library › Granted Patent US 12,427,149
Granted Patent B2
US 12,427,149 · App. 17/736,330 · Granted Sep 30, 2025

Methods and compositions for the prevention and treatment of hearing loss

Inventors: Jian Zuo (Carlsbad, CA); Tal Teitz (Carlsbad, CA)
Assignee: Ting Theropeutics, Inc.
A61K31/519A61K31/437A61K31/4439A61K31/4709A61K31/506A61P27/16
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,427,149
App. No.
17/736,330
Granted
Sep 30, 2025
Kind
B2
Abstract

Method, kit and pharmaceutical compositions using an inhibitor of EGFR signaling for prevention or treatment of hearing loss are described.

Claims (9)

1. A pharmaceutical composition comprising a synergistic combination of an inhibitor of epidermal growth factor receptor (EGFR) signaling comprising dabrafenib and a CDK2 inhibitor comprising AZD5438, wherein said synergistic combination protects against cisplatin induced and noise induced hearing loss in a mammal.

2. The pharmaceutical composition of claim 1 wherein the synergistic combination is formulated for oral delivery in a liquid carrier.

3. The pharmaceutical composition of claim 1 further comprised of: a sufficient amount of trametinib to prevent hearing loss due to cisplatin treatment.

4. The pharmaceutical composition of claim 3 wherein the sufficient amount of trametinib is 2 mg/kg in mice or an equivalent dosage for a human twice daily.

5. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition is formulated for oral delivery.

6. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition is formulated for a direct route of administration to the inner ear.

7. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition is formulated for parenteral delivery.

8. A kit formulated to protect against cisplatin induced hearing loss comprising: a synergistic combination of dabrafenib in an amount sufficient to prevent cisplatin induced hearing loss, and AZD5438 in an amount sufficient to prevent cisplatin induced hearing loss and cisplatin.

9. The kit of claim 8 , further comprising one or more protective or regenerative agents.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 25, 2024
From: ZUO, JIAN; TEITZ, TAL
To: TING THERAPEUTICS LLC
Reel/Frame 069018/0402 →
MERGER AND CHANGE OF NAME Recorded Oct 9, 2024
From: TING THERAPEUTICS LLC; TING THERAPEUTICS, INC.
To: TING THERAPEUTICS, INC.
Reel/Frame 069138/0580 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 4, 2022
From: TEITZ, TAL; ZUO, JIAN
To: TING THERAPEUTICS LLC
Reel/Frame 059811/0282 →
Continuity (4)
Division 17580755 · Jan 21, 2022
Continuation PCTUS2020063595 · Dec 7, 2020
Provisional Application 62947059 · Dec 12, 2019
Related Publication 20220265660A1 · Aug 25, 2022
References Cited (88)
US 7465728B2 · Newcombe et al. · 2008 [cited by applicant]
US 8703781B2 · Dumble et al. · 2014 [cited by applicant]
US 8937095B2 · Zahn et al. · 2015 [cited by applicant]
US 9258235B2 · Báder et al. · 2016 [cited by applicant]
US 9358235B2 · Bollag et al. · 2016 [cited by applicant]
US 9572815B2 · Zuo et al. · 2017 [cited by applicant]
US 9814714B2 · Ibrahim et al. · 2017 [cited by applicant]
US 9884868B2 · Kinsella et al. · 2018 [cited by applicant]
US 9938273B2 · Wu et al. · 2018 [cited by applicant]
US 10004803B2 · Mannick et al. · 2018 [cited by applicant]
US 10065934B2 · Cheng et al. · 2018 [cited by applicant]
US 10160755B2 · Lin et al. · 2018 [cited by applicant]
US 10286069B2 · Mannick et al. · 2019 [cited by applicant]
US 10428067B2 · Zhang et al. · 2019 [cited by applicant]
US 10449193B2 · Helson et al. · 2019 [cited by applicant]
US 10485791B2 · Wrobel et al. · 2019 [cited by applicant]
US 10639298B2 · Wrobel et al. · 2020 [cited by applicant]
US 10669296B2 · Martinez et al. · 2020 [cited by applicant]
US 10822337B2 · Gelman et al. · 2020 [cited by applicant]
US 10973809B2 · Miao et al. · 2021 [cited by applicant]
US 11024468B2 · Luo et al. · 2021 [cited by applicant]
US 11090307B2 · Wang et al. · 2021 [cited by applicant]
US 11141483B2 · Makings et al. · 2021 [cited by applicant]
US 11433073B2 · Zuo · 2022 [cited by examiner]
US 20090142337A1 · Squires · 2009 [cited by applicant]
US 20100021420A1 · Lyons et al. · 2010 [cited by applicant]
US 20130085112A1 · Collard et al. · 2013 [cited by applicant]
US 20140018372A1 · Maier et al. · 2014 [cited by applicant]
US 20140275183A1 · Yamamoto et al. · 2014 [cited by applicant]
US 20150140036A1 · Mannick et al. · 2015 [cited by applicant]
US 20150252428A1 · Comper et al. · 2015 [cited by applicant]
US 20150352086A1 · Koomen et al. · 2015 [cited by applicant]
US 20160089371A1 · Liu et al. · 2016 [cited by applicant]
US 20170143682A1 · Melin · 2017 [cited by applicant]
US 20170327557A1 · Chen · 2017 [cited by applicant]
US 20180015137A1 · Keizer · 2018 [cited by applicant]
US 20180161340A1 · Zuo et al. · 2018 [cited by applicant]
US 20180333411A1 · Srinivasan et al. · 2018 [cited by applicant]
US 20180338979A1 · Laquerre · 2018 [cited by examiner]
US 20190083521A1 · Klaus et al. · 2019 [cited by applicant]
US 20190209532A1 · Pelletier et al. · 2019 [cited by applicant]
US 20190233895A1 · Kurzrock et al. · 2019 [cited by applicant]
US 20190365897A1 · Garcia-Guzman et al. · 2019 [cited by applicant]
US 20190367903A1 · Domenyuk et al. · 2019 [cited by applicant]
US 20200030355A1 · Klaus et al. · 2020 [cited by applicant]
US 20200170872A1 · Lee et al. · 2020 [cited by applicant]
US 20210220300A1 · Cohen · 2021 [cited by applicant]
CA 2974623A1 · 2016 [cited by applicant]
CN 104211692A · 2014 [cited by applicant]
CN 104447701B · 2019 [cited by applicant]
CN 109475541A · 2019 [cited by applicant]
GB 201802307 · 2018 [cited by applicant]
WO 2015104292A3 · 2016 [cited by applicant]
WO 2016118014A2 · 2016 [cited by applicant]
WO 2016205806A1 · 2016 [cited by applicant]
WO 2017162510A1 · 2017 [cited by applicant]
WO 2018204226A1 · 2018 [cited by applicant]
WO 2019103984A1 · 2019 [cited by applicant]
WO 2020084105A3 · 2020 [cited by applicant]
WO 2022020114A2 · 2022 [cited by applicant]
WO 2022020114A3 · 2022 [cited by applicant]
Byth et al., “AZD5438, a potent oral inhibitor of cyclin-dependent kinases 1, 2, and 9, leads to pharmacodynamic changes and potent antitumor effects in human tumor xenografts,” Mol. Cancer Ther. Jul. 2009;8(7):1856-66.… [cited by examiner]
Tsai et al., “Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity,” Proc. Natl. Acad. Sci. U.S.A. Feb. 26, 2008;105(8):3041-46. PMID: 18287029. (Year: 2008). [cited by examiner]
Teitz et al., “CDK2 inhibitors as candidate therapeutics for cisplatin- and noise-induced hearing loss,” J. Exp. Med. 2018;215(4): 1187-203. PMID: 29514916. (Year: 2018). [cited by examiner]
Brighton, Hailey E., et al. “New mechanisms of resistance to MEK inhibitors in melanoma revealed by intravital imaging.” Cancer Research 78.2 (2018): 542-557. [cited by applicant]
Supplemental European Search Report in EP Application No. 20900420.9, dated Apr. 10, 2024, in 4 pages. [cited by applicant]
Search Report in CN Application No. 202080086445.X, dated Dec. 5, 2023, in 3 pages. [cited by applicant]
Amaravadi RK, Hamilton KE, Ma X, Piao S, Portillo AD, Nathanson KL, Carlino MS, Long GV, Puzanov I, Xu X, Morrissette JJ, Tsai KY, Flaherty KT, Sosman JA, Goodman GR, McArthur GA, Rustgi AK, Metz DC, Schuchter LM, Chapm… [cited by applicant]
Ascierto, P.A., Simeone, E., Sileni, V.C. et al. Sequential treatment with ipilimumab and BRAF inhibitors in patients with metastatic melanoma: data from the Italian ipilimumab expanded access programme (EAP). j. immuno… [cited by applicant]
Atikinson et al. “Hair Cell Regeneration after ATOH1 Gene Therapy in the Cochlea of Profoundly Deaf Adault Guinea Pigs,” PLoS ONE, Jul. 18, 2014 (Jul. 18, 2014), vol. 9, Iss. 7, pp. 1-11. entire document. [cited by applicant]
Boanza et al. “A primary role for the epidermal growth factor receptor in ommatidial spacing in the [cited by applicant]
Gautschi O, Milia J, Cabarrou B, Bluthgen MV, Besse B, Smit EF, Wolf J, Peters S, Früh M, Koeberle D, Oulkhouir Y, Schuler M, Curioni-Fontecedro A, Huret B, Kerjouan M, Michels S, Pall G, Rothschild S, Schmid-Bindert G,… [cited by applicant]
Groseclose MR, Laffan SB, Frazier KS, Hughes-Earle A, Castellino S. Imaging MS in Toxicology: an Investigation of Juvenile Rat Nephrotoxicity Associated with Dabrafenib Administration. J Am Soc Mass Spectrom. Jun. 2015;… [cited by applicant]
Harttrampf AC, Lacroix L, Deloger M, Deschamps F, Puget S, Auger N, Vielh P, Varlet P, Balogh Z, Abbou S, Allorant A, Valteau-Couanet D, Sarnacki S, Gamiche-Rolland L, Meurice G, Minard-Colin V, Grill J, Brugieres L, Du… [cited by applicant]
Hazlitt et al., “Development of Second-Generation CDK2 Inhibitors for the prevention of Cisplatin-Induced Hearing Loss,” J. Med Chem. Sep. 13, 2018:61(17):7700-7709. [cited by applicant]
Hecht M, Meier F, Zimmer L, Polat B, Loquai C, Weishaupt C, Forschner A, Gutzmer R, Utikal JS, Goldinger SM, Geier M, Hassel JC, Balermpas P, Kiecker F, Rauschenberg R, Dietrich U, Clemens P, Berking C, Grabenbauer G, S… [cited by applicant]
Jarman et al. “The role of Atonal transcription factors in the development of machanosensitive cells,” Seminars in Cell and Developmental Biology, May 1, 2013 (May 1, 2013, Vool. 24 Iss. 5, pp. 438-447. Entire document. [cited by applicant]
Johnson DB, Flaherty KT, Weber JS, Infante JR, Kim KB, Kefford RF, Hamid O, Schuchter L, Cebon J, Sharfman WH,McWilliams RR, Sznol M, Lawrence DP, Gibney GT, Burris HA 3rd, Falchook GS, Algazi A, Lewis K, Long GV, Patel… [cited by applicant]
Lampson BL, Nishino M, Dahlberg SE, Paul D, Santos AA, Jänne PA, Oxnard GR. Activity of erlotinib when dosed below the maximum tolerated dose for EGFR-mutant lung cancer: Implications for targeted therapy development. C… [cited by applicant]
Lee Young, International Search Report Written opinion concerning patentability PCT/US20/63595, International Searching Authority, Jun. 28, 2021, 1-5. [cited by applicant]
Liniker E, Menzies AM, Kong BY, Cooper A, Ramanujam S, Lo S, Kefford RF, Fogarty GB, Guminski A, Wang TW, Carlino MS, Hong A, Long GV. Activity and safety of radiotherapy with anti-PD-1 drug therapy in patients with met… [cited by applicant]
Menzies AM, Wilmott JS, Drummond M, Lo S, Lyle M, Chan MM, Thompson JF, Guminski A, Carlino MS, Scolyer RA, Kefford RF, Long GV. Clinicopathologic features associated with efficacy and long-term survival in metastatic m… [cited by applicant]
Prescribing information for TAFLINLAR (dabrafenib), revised Oct. 2019, retrieved from fda.gov on Apr. 12, 2022. (Year: 2019). [cited by applicant]
Theodore Howell, International Preliminary Report onPatentability PCT/US20/63595, International Preliminary Examination Authority, Nov. 3, 2021, 1-6. [cited by applicant]
Villaruz LC, Socinski MA, Abberbock S, Berry LD, Johnson BE, Kwiatkowski DJ, Iafrate AJ, Varella-Garcia M, Franklin WA, Camidge DR, Sequist LV, Haura EB, Ladanyi M, Kurland BF, Kugler K, Minna JD, Bunn PA, Kris MG. Clin… [cited by applicant]
DI Veroli et al. Combenefit: an Interactive Platform for the Analysis and Visualization of Drug Combinations Bioinfor. Adv. Access (Apr. 25, 2016). [cited by applicant]
Salehi P, Zallocchi M, Vijayakumar S, Urbanek M, Giffen KP, Li Y, Hati S, Zuo J. In silico transcriptomics identifies FDA-approved drugs and biological pathways for protection against cisplatin-induced hearing loss. Rev… [cited by applicant]
Vijayakumar S, DiGuiseppi JA, Dabestani J, Ryan WG, Vielman Quevedo R, Li Y, Diers J, Tu S, Fleegel J, Nguyen C, Rhoda LM, Sajid Imami A, Ali Hamoud A, Lovas S, McCullumsmith R, Zallocchi M, Zuo J. In Silico Transcripto… [cited by applicant]